Opendata, web and dolomites

SULIPRO

A scientifically proven, safe, naturally derived drug for the effective treatment of liver damage - an innovative solution for a significant unmet medical need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SULIPRO project word cloud

Explore the words cloud of the SULIPRO project. It provides you a very rough idea of what is the project "SULIPRO" about.

successful    compounds    parallel    sulipro    nafld    drugs    specialised    builds    unless    scarring    first    prescribed    consumers    animal    non    permanent    24    prevalence    diseases    natural    cirrhosis    ing    proven    amount    supplements    million    seriously    expects    inflammation    stages    liver    fatty    trials    once    steatohepatitis    soy    fat    33    months    models    medical    price    otc    market    botanical    causing    26    undergone    nash    preclude    patients    demonstrating    physician    funds    online    treatment    population    foods    food    showing    private    alcoholic    pharmacies    trial    drug    progress    shops    functions    small    shield    transplant    raised    amazon    combination    fda    counter    company    impair    safe    commercialised    eur    web    disease    therapeutic    approved    humans    maintains    clinical    affordable    positive    oral    made    death    efficacy    scientifically    distributor    financial   

Project "SULIPRO" data sheet

The following table provides information about the project.

Coordinator
NATURAL SHIELD ISRAEL 2016 LIMITED 

Organization address
address: AD GORDON 13
city: HERZLIYA
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://natshield.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NATURAL SHIELD ISRAEL 2016 LIMITED IL (HERZLIYA) coordinator 50˙000.00

Map

 Project objective

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver causing inflammation and eventually lead to permanent scarring (cirrhosis), which can seriously impair the liver’s ability to functions. NAFLD can progress to non-alcoholic steatohepatitis (NASH), and then to liver failure resulting in death unless there is a liver transplant. The prevalence of NAFLD in Europe is estimated to be between 26 and 33% of the general population. Currently, there is no available therapeutic treatment for patients with NAFLD and NASH. Natural Shield have developed a specialised oral therapeutic, called SULIPRO, which is a combination of soy derived compounds, that has been proposed as a novel scientifically proven safe treatment for patients in the early stages of NAFLD and NASH. Current drugs produced for liver diseases have a large amount of side effects and high financial costs that may preclude their long-term use in patients with NAFLD or the early stages of NASH. SULIPRO has already undergone positive clinical trials in animal models and successful Phase I clinical trials in humans showing demonstrating no side effects and high efficacy. The company now requires funding for a small Phase II trial. Once commercialised SULIPRO will be made available to consumers at an affordable price, as an over the counter (OTC) drug, available in shops/pharmacies and on the web, using an online distributor, such as Amazon. Natural Shield maintains its own research program involved in developing in parallel OTC food supplements, physician-prescribed medical foods, and FDA-approved botanical drugs. The company expects to reach the market with its first products within 24 months and thus far has raised over 5 million EUR in private funds.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SULIPRO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SULIPRO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More